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The coronavirus (CoV) is a single‐stranded enveloped virus, belonging to the family Coronaviridae, with a positive‐sense RNA genome about 26‐32 kb in size. It is widespread among humans and other mammals, such as camels, bats, masked palm civets, mice, dogs, and cats.[^1^](#ctm217-bib-0001){ref-type="ref"}, [^2^](#ctm217-bib-0002){ref-type="ref"} Two viruses, severe acute respiratory syndrome coronavirus (SARS‐CoV)[^3^](#ctm217-bib-0003){ref-type="ref"} and MERS‐CoV,[^4^](#ctm217-bib-0004){ref-type="ref"} have had a significant impact on humans over the past two decades, although most CoVs cause mild clinical symptoms in humans. In December 2019, pneumonia with an unknown cause broke out in Wuhan, China,[^5^](#ctm217-bib-0005){ref-type="ref"} which was different from SARS‐CoV and MERS‐CoV. This new type of CoV is the seventh family member of CoV to infect humans.[^6^](#ctm217-bib-0006){ref-type="ref"} The International Virus Classification Commission has renamed the virus, previously temporarily named 2019‐nCoV, as severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), and WHO has announced a new name for this epidemic: coronavirus disease (COVID‐19).[^7^](#ctm217-bib-0007){ref-type="ref"} Genome sequencing found it to be a beta CoV with at least 70% genetic‐sequence similarity to SARS‐CoV. We summarized clinical phenomes of 3795 patients with SARS‐CoV‐2 infection from 80 international and national reports (Supporting Information Table 1) since the outbreak, mainly including complaints and signs (3795 patients in Table [1](#ctm217-tbl-0001){ref-type="table"}), biochemical measurements (3085 patients in Table [2](#ctm217-tbl-0002){ref-type="table"}), and imaging information with an autopsy report (2856 patients in Tables [3](#ctm217-tbl-0003){ref-type="table"} and [4](#ctm217-tbl-0004){ref-type="table"}). There is only one autopsy report because there is less information in this field, but understanding the pathogenesis of COVID‐19 may also help doctors make treatment plans, so we also included them.

###### 

Patient complaint‐ and physical examination‐based phenomes

  Phenomes                                Sum/number   Phenomes                      Sum/number   Phenomes                      Sum/number                 Phenomes                             Sum/number          Phenomes                  Number/mean ± SE
  --------------------------------------- ------------ ----------------------------- ------------ ----------------------------- -------------------------- ------------------------------------ ------------------- ------------------------- ------------------
  General information                                  Nasal congestion              82           Myalgia or arthralgia         365                        Hepatitis B infection                26                  Arrhythmia                23
  Patient number                          3795                                                    Chill                         188                        COPD                                 51                  ARDS                      99
  Male                                    2081         Little phlegm                 57           Abdominal pain and diarrhea   7                          Chronic lung disease                 26                  AKI                       5
  Female                                  1705         Sputum                        586          Dyspnea                       188                        Cardiac or cardiovascular disease    205                 Respiratory failure       11
  Age                                     46.48        Blood in sputum               3            Chest tightness and dyspnea   83                         Never smoked                         927                 Hepatic insufficiency     2
  Clinical classification                              Myalgia or fatigue            103          Shortness of breath           323                        Former smoker                        29                  Renal insufficiency       14
  Mild type                               37           Mild headache and dizziness   8            Chest distress                136                        Current cigarette smoker             196                 Secondary infection       4
  Moderate type                           487          Coarse breath sounds          3            Chest pain                    41                         Cerebrovascular disease              32                  DIC                       1
  Severe type                             331          Rhinorrhea                    65           Rhonchi                       4                          Cardiovascular and cerebrovascular   53                  Rhabdomyolysis            2
  Critically ill type                     8                                                       Moist rales                   2                          Malignancy                           24                  Co‐infection              
  Signs and symptoms                                   Sneeze                        5            Conjunctivitis                1                          Chronic kidney disease               25                  Other viruses             0
  No obvious symptom                      184          Weakness                      7            Conjunctival congestion       9                          HIV infection                        2                   Bacteria                  1
  Fever                                   1703         Sore throat                   297                                                                   Bacterial co‐infections              2                   Fungus                    4
  Higher temperature                      86.8         Agrypnia                      22           Hemoptysis                    2                          Digestive system disease             31                                            
  Normal                                  2            Gastrointestinal symptoms     Confusion    9                             Endocrine system disease   27                                   PaO~2~ (83‐108)     93.76 ± 4.40              
  \<37.3°C                                742          Loss of appetite              208          Upper airway congestion       8                          Nervous system disease               2                   PaO~2~:FIO~2~ (400‐500)   207.84 ± 35.92
  37.3‐38.0°C                             541          Nausea and vomit              216          Signs of infection                                       Immunodeficiency                     6                   SaO~2~ (≥95%)             75.43 ± 5.79
  38.1‐39.0°C                             483          Nausea                        60           Throat congestion             19                         Hyperlipidemia                       22                  Decreased                 9
  \>39.0°C                                132          Vomit                         20           Tonsil swelling               23                         Cholelithiasis                       6                   PaCO~2~ (35‐48)           36.69 ± 1.10
  Fatigue                                 943          Diarrhea                      187          Enlargement of lymph nodes    2                          Thyroid diseases                     9                   Heart rate mean           91.85 ± 0.92
  Headache                                290          Gastrointestinal reaction     1            Rash                          2                          Urolithiasis                         3                   Respiratory mean          21.70 ± 0.15
  Headache and mental disorder symptoms   13           Abdominal pain                14           Comorbidities                                            Stroke                               3                   MAP                       90.00 ± 0.00
  Dizziness                               39           Belching                      7            Diabetes                      214                        Complications                        Systolic pressure   131.82 ± 1.36             
  Dizziness or headache                   7            Constipation                  48           Hypertension                  415                        Shock                                32                  Diastolic pressure        79.57 ± 0.94
  Cough                                   1986         Hemoptysis                    17           Chronic liver disease         40                         Acute cardiac injury                 16                                            

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; DIC, disseminated intravascular coagulation; MAP, mean arterial pressure; PaCO~2~, partial pressure of carbon dioxide in artery; PaO~2~:FIO~2~, partial pressure of oxygen:fraction of inspiration O~2~; PaO~2~, partial pressure of oxygen; SaO~2~, arterial oxygen saturation.

John Wiley & Sons, Ltd.

###### 

Biochemical‐ and molecular measurements‐based phenomes

  Phenomes                Number/mean ± SE   Phenomes                       Number/mean ± SE   Phenomes                  Number/mean ± SE           Phenomes                  Number/mean ± SE   Phenomes                     Number/mean ± SE
  ----------------------- ------------------ ------------------------------ ------------------ ------------------------- -------------------------- ------------------------- ------------------ ---------------------------- ------------------
  Inflammatory cells                         Platelets (125‐350)            180.92 ± 1.94      Amyloid A (\<10)          237.73 ± 55.51             D‐dimer (\<0.55)          16.14 ± 4.15       Creatine kinase (\<171)      103.01 ± 5.05
  Patient number          3085               Increased                      10                 Increased                 14                         Increased                 262                ≥200 U/L                     90
  WBC (3.5‐9.5)           5.53 ± 0.05        Decreased                      24                 Normal                    4                          Normal                    2                  Creatine kinase--MB (\<25)   13.03 ± 1.53
  Increased               81                 Normal                         1                  Ferritin (21.0--274.7)    808.7 ± 0.00               FDP (1‐5)                 4.00 ± 0.00        CTnl (0‐0.1)                 0.53 ± 0.22
  Decreased               230                Haemoglobin (110‐160)          137.10 ± 1.04      CD3 (723‐2737)            363.74 ± 90.37             AT (80‐120)               91.00 ± 0.00       LDH (125‐243)                277.98 ± 6.12
  Normal                  202                Decreased                      1                  Decreased                 28                         Blood biochemistry        Increased          13                           
  Neutrophils (1.8‐6.3)   15.37 ± 1.97       Normal                         10                 CD4 (404‐1612)            244.08 ± 34.04             Lactate (0.5--2.0)        1.20 ± 0.05        Myoglobin (0‐110)            58.69 ± 4.59
  Increased               43                 Eosinophils (0.02‐0.52)        0.05 ± 0.00        Decreased                 60                         Albumin (40‐55)           34.89 ± 0.94       Glucose (3.9‐6.1)            8.13 ± 0.49
  Decreased               47                 Increased                      2                  IL‐6 (0.1‐2.9)            149.66 ± 62.27             Alanine ATase (9‐50)      32.95 ± 0.97       BNP (0‐23.1)                 43.90 ± 0
  Normal                  54                 Decreased                      14                 CD8 (220‐1129)            247.08 ± 32.54             Increased                 160                HT‐I (\<26.2)                4.90 ± 0.75
  Lymphocytes (1.1‐3.2)   1.72 ± 0.14        Normal                         29                 Decreased                 20                         Aspartate ATase (15‐40)   35.48 ± 0.78       K (3.5‐5.5)                  4.05 ± 0.10
  Increased               1                  Infection‐related biomarkers   CD19               72.77 ± 15.89             Increased                  171                       Decreased          10                           
  Decreased               347                Procalcitonin (\<0.05)         0.25 ± 0.04        CD 16 (\<56)              64.21 ± 20.61              TG (\<1.70)               1.14 ± 0.00        Na (136‐146)                 137.72 ± 0.35
  Normal                  24                 Increased                      71                 Coagulation function      Total bilirubin (4.7‐24)   15.67 ± 1.72              Cl (96‐106)        98.77 ± 1.00                 
  RBC (3.5‐5.5)           4.45 ± 0.14        Normal                         95                 Thrombin time s (16‐18)   28.90 ± 0.00               Increased                 78                 Decreased                    15
  Monocytes (0.1‐0.6)     0.46 ± 0.04        ESR (20 mm/h)                  35.44 ± 1.21       APTT (25.1‐36.5)          32.02 ± 0.62               BUN (2.8‐7.6)             4.74 ± 0.00        PH (7.35‐7.45)               7.42 ± 0.00
  Increased               10                 CRP (0‐10)                     38.01 ± 1.49       PT (9.4‐12.5)             12.58 ± 0.16               Serum urea (2.5‐7.1)      3.80 ± 0.00        Increased                    21
  Decreased               3                  Increased                      870                Fibrinogen (2‐4)          5.23 ± 0.52                Decreased                 3                  decreased                    4
  Normal                  16                 Normal                         66                 Increased                 12                         Creatinine (64‐104)       68.19 ± 1.45       Lactate (0.5‐1.6)            1.30 ± 0.00
                                                                                                                                                    Increased                 15                                              
                                                                                                                                                    Decreased                 2                                               

Abbreviations: APTT, activated partial thromboplastin time; AT, angiotensin; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CD16, cluster of differentiation 16; CD19, cluster of differentiation 19; CD3, cluster of differentiation 3; CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; Cl, chlorine; CRP, C‐reactive protein; CTn1, cardiac troponin 1; ESR, erythrocyte sedimentation rate; FDP, fibrin degradation product; HT‐I, hypersensitive troponin I; IL‐6, interleukin‐6; K, potassium; LDH, lactate dehydrogenase; M, mean; Na, sodium; PH, potential of hydrogen; PT, prothrombin time; RBC, red blood cell count; TG, triglyceride; WBC, white blood cell count.
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###### 

Imaging‐based phenomes, eg radiographs, ultrasounds, pathology

  Phenomes                                                       Sum/number   Phenomes                        Sum/number   Phenomes                                  Sum/number                 Phenomes                                   Sum/number
  -------------------------------------------------------------- ------------ ------------------------------- ------------ ----------------------------------------- -------------------------- ------------------------------------------ ------------
  Phenomes                                                       SUM          Pleural impairment              2            Right                                     28                         Crazy paving pattern                       51
  Patient number                                                 2856         Pleural thicken                 15           Left upper lobe                           187                        Peripheral distribution                    7
  Normal                                                         75           Pleural effusion                21           Left lower lobe                           285                        Peribronchovascular                        1
  Patchy                                                         491          Pericardial effusion            8            Left                                      19                         Scattered opacities                        1
  GGO/consolidation                                              18           Lymphadenopathy                 9            Upper lobes                               43                         Ill‐defined                                1
  GGO without consolidation                                      12           Lobe affected                                Middle lobe                               30                         Other findings                             
  GGO with consolidation                                         113          0                               24           Lower lobes                               51                         Discrete pulmonary nodules                 14
  Consolidation                                                  119          1                               102          Predominant distribution                  Lymph node enlargement     9                                          
  Parenchymal abnormalities                                      3            2                               59           Anterior                                  9                          Fibrous stripes                            35
  Spider web sign                                                20           3                               56           Posterior                                 42                         Cystic changes                             8
  Ill‐defined margins                                            124          4                               62           Inferior                                  2                          Bronchiectasis                             11
  GGOs with interstitial and/or interlobular septal thickening   147          5                               136          Peripheral                                152                        Adjacent pleura thickening                 77
  GGO                                                            999          \>2 lobes                       70           Subpleural region                         45                         Interlobular septa thickening              1
  Patchy/punctuated GGO                                          105          Unilateral lung                 107          Central                                   5                          Interstitial abnormalities                 143
  GGO were bilateral                                             182          Bilateral lung disease          1119         Diffuse distribution                      43                         Pleura thickening                          1
  GGO involving the posterior lungs                              41           Bilateral upper lobes           67           Peribronchial distribution                3                          Qualitative change on follow‐up chest CT   
  GGO involving the peripheral                                   44           Bilateral lower lobes           72           Both central and peripheral               1                          No change                                  1
  Air bronchogram                                                165          Frequency of lobe involvement                Mixed distribution                        26                         Disease improvement                        1
  Bronchial wall thickening                                      9            Right upper lobe                181          Opacification distribution and patterns   Mild disease progression   7                                          
  reticulation                                                   23           Right middle lobe               124          Rounded morphology                        7                          Moderate disease progression               2
                                                                              Right lower lobe                306          Linear opacities                          58                         Severe disease progression                 1

Abbreviation: GGO, ground‐glass opacity.
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###### 

Pathological characteristics of postmortem biopsies

  Phenomes                                            Sum/number   Phenomes                                            Sum/number
  --------------------------------------------------- ------------ --------------------------------------------------- ------------
  Patient number                                      1            Viral cytopathic‐like changes                       1
  Histological examination                                         Intranuclear or intracytoplasmic viral inclusions   0
  Bilateral                                           1            Liver biopsy                                        
  Alveolar damage                                     1            Microvesicular steatosis                            
  Cellular fibromyxoid exudates                       1            Mild                                                
  Desquamation of pneumocytes                         1            Moderate                                            1
  Hyaline membrane formation                          1            Severe                                              
  Pulmonary oedema                                    1            Lobular and portal activity                         
  Interstitial mononuclear inflammatory infiltrates   1            Mild                                                1
  Multinucleated syncytial cells                      1            Moderate                                            
  Atypical enlarged pneumocytes                       1            Severe                                              
  Large nuclei                                        1            Interstitial mononuclear inflammatory infiltrates   1
  Amphophilic granular cytoplasm                      1            Heart tissue                                        
  Nucleoli in the intra‐alveolar spaces               1            No substantial damage                               1
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The most common clinical phenomes of patients were fever, malaise, dry cough, shortness of breath, and respiratory distress, as reported initially.[^8^](#ctm217-bib-0008){ref-type="ref"} One study showed that about 66% of patients had a history of exposure to a wet market in Wuhan, of whom 73% were males and \<50% suffered from underlying diseases, including diabetes, high blood pressure, and cardiovascular diseases. More than 90% had fever ranging between 38 and 39°C and bilateral chest abnormalities on radiography, 76% had cough, 63% had reduced lymphocyte number, 55% dyspnea, 44% fatigue, 28% sputum, 25% low white blood cell counts, as well as other clinical features, including headache, hemoptysis, diarrhea, or hypertension.[^9^](#ctm217-bib-0009){ref-type="ref"} It would be more beneficial to set up a digital evaluation score system to present the variety of clinical phenomes and integrate with molecular multi‐omics data. Table [1](#ctm217-tbl-0001){ref-type="table"} shows that the number of male patients was higher than that of females, with an average age of 46.48 years. The most common phenomes are fever, cough, fatigue, sputum, myalgia, sore throat, and shortness of breath, as summarized from more than 80 published studies (Supporting Information Table 1).

In addition, clinical phenomes related with gastrointestinal phenomes, for example, nausea or vomiting were also noticed.[^10^](#ctm217-bib-0010){ref-type="ref"} The history of exposure to susceptibility factors is one of the critical factors in the diagnosis, including visit to the seafood market, travel through infected area, or contact with people with infection.[^11^](#ctm217-bib-0011){ref-type="ref"} Radiomics‐based phenomes become more important in the early diagnosis and dynamic monitor of disease progression. Imaging phenomes of SARS‐CoV‐2‐infected pneumonia can be detected about 9 days after the first visit to the clinic, and turbid basal striations in both lower lobes of lungs are shown at about 10 days, during which the rale lung sound could be heard.[^10^](#ctm217-bib-0010){ref-type="ref"} Multiple peripheral ground‐glass opacities appeared in both lobes of lungs in some patients.[^12^](#ctm217-bib-0012){ref-type="ref"} From the preliminary analysis of about 80 clinical reports (Supporting Information Table 1), about 75% (2856/3795 patients) had chest CTs that showed ground‐glass opacity, patchy shadowing, and bilateral lower‐lobe inflammation as common radiographic features of patients with COVID‐19 infection. The progression of COVID‐19‐infected lung injury is described by increased density, profusion, confluence, and pleural effusion in chest radiographs[^6^](#ctm217-bib-0006){ref-type="ref"} (Table [3](#ctm217-tbl-0003){ref-type="table"}). In a study of 159 asymptomatic patients, we collected chest CT imaging of most patients that showed ground‐glass opacity shadows, of which 82 were pure ground‐glass opacity shadows, and 17 cases presented ground‐glass opacity with consolidation. Among patients with asymptomatic infections, a chest CT scan is particularly important to facilitate early detection of suspected cases and guide early isolation. There is an urgent need to develop a mode of artificial intelligence analysis to generate more detailed imaging phenomes and digitalize the image abnormality of density, size, distribution, and geometric figures.

Table [2](#ctm217-tbl-0002){ref-type="table"} demonstrates that the number of lymphocytes, CD3, and CD4 reduced, whereas levels of C‐reactive protein, D‐dimer, thrombin time, and lactate dehydrogenase increased in patients with SARS‐CoV‐2 infection. When collecting patient information from multiple studies, because the data were obtained from different hospitals and laboratory platforms have certain differences, different data units were unified and then collated, some indicators have a large difference in normal range, only recorded the abnormal number of people rather than specific values, and others without the specific value also recorded the number of people. The SARS‐CoV‐2 nucleic acid test kit was being developed rapidly, with a clear improvement in sensitivity, based on different biotechnologies. The rapid development and breakthrough of SARS‐CoV‐2 kits were carried out by immediately integrating and collaborating multidisciplinary resources and efforts and by swiftly translating new technologies, gene sequencing, and bioinformatics into clinical practice.[^13^](#ctm217-bib-0013){ref-type="ref"} Biochemical phenomes become critical criteria to confirm SARS‐CoV‐2 infection, for example, isolation of SARS‐CoV‐2, real‐time reverse‐transcriptase PCR assay, or SARS‐CoV‐2 full‐genome sequencing.[^11^](#ctm217-bib-0011){ref-type="ref"} The latest edition of the National Health Commission, the seventh edition of the new CoV pneumonia diagnosis and treatment program, in addition to nucleic acid detection and sequencing also increased serological testing as the basis for diagnosis. That means detecting new CoV‐specific IgM antibodies and following IgG‐positive or new CoV‐specific IgG antibodies from negative to positive or recovery period from four times higher than the acute phase can also be diagnosed. The genomes of SARS‐CoV‐2 are closely related to those of two bat‐derived SARS‐like CoVs, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21, but different from SARS‐CoV (about 79%) and MERS‐CoV (about 50%). However, the homology modeling indicated that SARS‐CoV‐2 has receptor‐binding domain structures, similar to that of SARS‐CoV,[^14^](#ctm217-bib-0014){ref-type="ref"} although there are some differences in the key residues.

In addition to diagnosis, clinical phenomes of patients with SARS‐CoV‐2 add significant impact to dynamically differentiate it from other diseases, predict the disease severity, and monitor the therapeutic effect, although the specificity should be furthermore defined. Pulmonary edema with hyaline membrane formation, inflammatory cell infiltration (mainly lymphocytes), multinucleated syncytial cells in alveolar space were observed in lung autopsy tissue of patients with SARS‐CoV‐2 (Table [4](#ctm217-tbl-0004){ref-type="table"}), similar to those with SARS‐CoV and MERS‐CoV infections.[^16^](#ctm217-bib-0016){ref-type="ref"}, [^17^](#ctm217-bib-0017){ref-type="ref"} Liver biopsy specimens from COVID‐19 patients showed moderate microcapsule steatosis and mild lobular and portal activity, which might have been damaged directly by SARS‐CoV‐2 infection or drug‐associated toxicity. Among them, imaging information and genetic detection play important roles. For example, pneumonia of SARS‐CoV‐2 infection should be differentiated from that of mycoplasma pneumonia and community‐acquired pneumonia, which often occur in children and adolescents with a clear seasonal trend. Nucleic acid amplification test can be used in the acute phase of the disease, combined with serological testing, to reduce potential false negative results.[^15^](#ctm217-bib-0015){ref-type="ref"} Clinical phenomes of mycoplasma pneumonia mainly include alterations in the lower‐middle lung area, tracheobronchitis, mucinous or mucous purulent sputum, headache, sore throat, rhinitis, and otitis media. The scoring system of clinical phenomes was developed to identify mycoplasma and guide patient management and adjuvant antimicrobial therapy, with 83% sensitivity.[^16^](#ctm217-bib-0016){ref-type="ref"} Clinical phenomes of patients with SARS‐CoV included dyspnea, recurrent or persistent fever, new pneumonia infiltration on chest imaging, for example, multifocal airspace merger in the lower lung, and ground‐glass opacity with consolidation.[^3^](#ctm217-bib-0003){ref-type="ref"} Patients with MERS‐CoV in 2012 had clinical phenomes including fever, cough, dyspnea, and pneumonia, like any other lower respiratory diseases, but also had rapidly developing acute respiratory distress syndrome, multiple‐organ failure, and death. Compared with SARS‐CoV, MERS‐CoV develops faster into respiratory failure and causes acute kidney damage.[^17^](#ctm217-bib-0017){ref-type="ref"}

However, there is a lack of clinical phenomes related to the mental health aspect of patients with SARS‐CoV‐2 or SARS‐CoV and MERS‐CoV, suspected people with the infections, as well as the normal population, during the early stage, duration, and late stage of infection. The abnormality of mental phenomes can reflect the living environment and influence the quality of people\'s lives, although the impact on diagnosis and treatment remain unclear. The COVID‐19‐associated phobia, depression, and over‐responses should be investigated in patients with infection, suspected candidates, relatives, and people in the society. It is important to develop an artificial intelligence evaluation scoring system to dynamically monitor phenomes of mental health as part of the clinical phenomes and enable application to a large number of suspected people before definitive diagnosis and treatment.

Clinical phenomes should be given the priority in the diagnosis and treatment of COVID‐19. The development of SARS‐CoV‐2 infection‐associated phenome list required efficient and professional manpower and a big data‐based technology in a short and high‐pressure period during a sudden outbreak. The artificial intelligence system can help medical staff to automatically collect, achieve, analyze, and optimize databases of clinical phenomes, and offer an immediate response and indication of the patient\'s health condition. Such an evaluation system will speed up the diagnosis and save a lot of clinical manpower and resources. The digitalized lung imaging analysis system can effectively quantify dynamic changes of the lung tissue and assist clinical judgment and decision‐making. The system should have the capacity for artificial intelligence‐based machine learning to analyze radiomics‐ or imaging‐based data (eg, pathology, computed tomography, ultrasound, and echocardiography), patient‐based information (eg, complaints, feelings, history, and potential factors), clinician‐based records (eg, signs, observations, and questions), and molecular measurements‐based digitals (eg, biochemistry, liquid biopsies, multi‐omics, and RNA and DNA sequencing). The system should also be able to automatically be optimized and updated, to build multi‐dimensional models and perform deep learning, and carry out the application of clinical trans‐omics for diagnosis and treatment of patients with SARS‐CoV‐2 infection. In addition to the role discussed above, artificial intelligence also plays an important role in other aspects. Currently, during the initial implementation, recording travel of people during the outbreak and using the internet and artificial intelligence technology to provide online consultation services based on the information obtained from pre‐examination, artificial intelligence can make a preliminary judgment of the information, and give preliminary advice and recommendations for the doctor\'s reference. There is also an infrared body temperature monitoring system. Artificial intelligence can automatically analyze images captured by thermal imagers and 3D laser cameras, identify and depict human facial features from the images, measure human forehead temperature, and automatically record it. The driverless delivery vehicle would also be responsible for the distribution of some medical and living materials, which is also inseparable from artificial intelligence technology. Artificial intelligence is also playing an important role in forecasting outbreaks and determining the direction of personnel outflow through data orientation and analysis, as well as assisting drug development. Such a system will be of benefit when aiming to control the outbreak of unknown or unexpected infections in the future.

This article is a preliminary retrospective analysis. When collecting information, the patient information in the raw data was insufficient to allow us to further group the patients. In conclusion, we summarized clinical phenomes of patients with SARS‐CoV‐2 based on published studies to emphasize the importance and specificity of those phenomes in diagnosis and treatment of infection, and evaluate the impact on medical services. Clinical phenomes of SARS‐CoV‐2 infection were compared with those of SARS‐CoV and MERS‐CoV infections. There is an urgent need to develop a system with artificial intelligence‐based machine learning capacity to analyze and integrate radiomics‐ or imaging‐based, patient‐based, clinician‐based, and molecular measurements‐based data, to fight the outbreak of COVID‐19 and enable more efficient responses to unknown infections in the future.
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